About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

JNJ-64565111

Company: Janssen Research & Development, LLC
Mechanism: Mechanism not yet reported
Route: Route not yet reported
Recruiting trials: None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details

Terminated NCT NCT02862431

Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64565111 in Type 2 Diabetes Mellitus (T2DM)

Not yet reported Janssen Research & Development, LLC 24 participants Est. completion 2016-12-05 1 site Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT03235219

A Phase 1b Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of JNJ-64565111 in Participants With Type 2 Diabetes Mellitus

Not yet reported Janssen Research & Development, LLC 39 participants Est. completion 2018-02-19 2 sites Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT03486392

A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants

Not yet reported Janssen Research & Development, LLC 474 participants Est. completion 2019-03-08 51 sites Stand-alone

Other conditions: Obesity
View official trial listing →
Completed NCT NCT03546205

A Study to Evaluate JNJ-64565111 Pharmacokinetics and Safety in Adult Participants With Varying Degrees of Renal Function

Not yet reported Janssen Research & Development, LLC 40 participants Est. completion 2018-12-17 2 sites Stand-alone

Other conditions: Kidney Failure, Chronic
View official trial listing →
Completed NCT NCT03586830

A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Participants With Type 2 Diabetes Mellitus

Not yet reported Janssen Research & Development, LLC 196 participants Est. completion 2019-04-05 27 sites Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT03586843

A Study of JNJ-64565111 After Single Subcutaneous Administration at Different Injection Sites in Otherwise Healthy Overweight/Obese Adult Participants and a Study of JNJ-6456511 in Otherwise Healthy Obese Adult Participants After Multiple Dose

Not yet reported Janssen Research & Development, LLC 52 participants Est. completion 2019-03-17 1 site Stand-alone

Other conditions: Obesity
View official trial listing →
Completed NCT NCT03606057

A Study to Investigate the Effect of JNJ-64565111 on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy Adults: a Thorough ECG Study Employing Placebo, JNJ-64565111, and a Positive Control (Moxifloxacin)

Not yet reported Janssen Research & Development, LLC 188 participants Est. completion 2019-02-28 1 site Stand-alone

Other conditions: Healthy
View official trial listing →
Terminated NCT NCT03618160

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Subcutaneous (SC) Injections of JNJ-64565111 in Healthy Male Japanese Participants and to Assess Pharmacokinetics Following Subcutaneous Injections of JNJ-64565111 in Healthy Male Caucasian Participants

Not yet reported Janssen Pharmaceutical K.K. 42 participants Est. completion 2019-06-21 2 sites Stand-alone

Other conditions: Healthy
View official trial listing →
Completed NCT NCT04944992

A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)

Not yet reported Merck Sharp & Dohme LLC 145 participants Est. completion 2022-10-19 69 sites

MASLDMASH
View official trial listing →
Completed NCT NCT05877547

A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)

Not yet reported Merck Sharp & Dohme LLC 381 participants Est. completion 2025-12-29 175 sites

MASLDMASH Other conditions: Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic
View official trial listing →
Completed NCT NCT06052566

A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014)

Not yet reported Merck Sharp & Dohme LLC 22 participants Est. completion 2024-12-05 4 sites

Other conditions: Non-alcoholic Steatohepatitis, Hepatic Impairment
View official trial listing →
Completed NCT NCT06482112

Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)

Not yet reported Merck Sharp & Dohme LLC 124 participants Est. completion 2025-06-27 39 sites

MASLD Other conditions: Non-alcoholic Fatty Liver Disease, Liver Disease
View official trial listing →
Completed NCT NCT06836037

A Clinical Study of Efinopegdutide (MK-6024) in Healthy Chinese Volunteers (MK-6024-011)

Not yet reported Merck Sharp & Dohme LLC 56 participants Est. completion 2023-02-02 1 site

Other conditions: Healthy
View official trial listing →

Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

ClinicalTrials.gov — NCT03235219

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.